Skip to content

MBX Biosciences, Inc. MBX Return on assets

Return on assets at other companies

Eli Lilly logo
Eli LillyLLY
24.5%+10.1pp
Amgen logo
AmgenAMGN
8.6%+2.1pp
Viking Therapeutics logo
Viking TherapeuticsVKTX
-64%-88.9pp
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-58.5%-7.6pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-64.8%-9.5pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-47.2%+2.5pp

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s return on assets?
MBX Biosciences, Inc. (MBX) reported return on assets of -24.8% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.